Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q1 2016 call → NOWe need to determine if management conveys that the company's current business is visibly outgrowing its own size, i.e., there is a disproportion between the company's smallness and the scale of what is currently arriving. Look for statements about large orders, single customers, or commitments that are large relative to the company. In the transcript, management discusses various product lines. Key points: - Funnel Cakes up 58%, but that's a growth rate, not necessarily a disproportion. - Churros up 7%, etc. - Soft pretzels down. - Handheld sales down. - ICEE and frozen beverages up 17%, with gallon sales up 11%. - Service revenue up 16%. Management mentions "We have a lot of targets in the fire" and "lots of good opportunities" but that's generic. Specifically, there is a mention of a major customer for handheld products: "We’ve a major customer that we’ve been dealing with for almost two years and we’ve a backlog of products that we’re making for them out of one of our handheld plants, its going to last in the early spring." That suggests a significant order, but is it large relative to the company? The company is J&J Snack Foods, which has revenue around $1 billion? Actually, from the call, net sales increased 5% for the quarter, and net earnings $12.5 million. The company is not tiny; it's a mid-cap. The question asks if the company is small relative to what is happening. Management does not explicitly say "we are small" or that a single customer is large relative to the company. They mention a major customer with a backlog, but they don't quantify it as a large share of revenue. Also, they mention new products like OREO churros and Pillsbury, but that's about $7 million annualized, which is small relative to the company's revenue (likely over $1 billion). So no disproportion. Management also talks about "we appear to be hitting on most of our cylinders" and "best days are yet to come" but that's not a disproportion. The question specifically asks: "does management describe current activity, demand, or commitments arriving at a scale that is large relative to how small the company still is?" The company is not small; it's a established player. There is no indication that a single customer or contract could rival the company's size.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.